Scholarlink

Purpose <p>Gastrointestinal stromal tumors (GISTs), the most common gastrointestinal sarcomas, experience a high rate of resistance to standard treatment tyrosine kinase inhibitor (TKI) imatinib, leading to tumor progression. Identifying non-responders and offering precise alternatives are crucial, however, multi-omics studies of GIST are limited, which hinders GIST biology understanding and novel drug development.</p> Methods <p>We performed whole-exome and transcriptomic sequencing on 106 primary GIST patients. Subtype-specific molecular features and therapeutic responses were further validated in vitro and in vivo.</p> Results <p>Unsupervised clustering analysis of RNA data classified them into four subtypes, including immune (G1), stromal (G2), proliferative (G3), and metabolic (G4) subtypes. The G4 subtype had more patients with primary non-gastric tumors, a poor response to neoadjuvant imatinib treatment and synchronous metastasis, with an overall poor prognosis. Notably, G4 subtype exhibited significantly enhanced aerobic metabolism. Moreover, G4 subtype harbored homologous recombination repair deficiency (HRD) signatures, with significantly reduced homologous recombination activity and upregulation of non-homologous repair pathways. By stratifying GIST cell lines into subtypes, we confirmed that the HRD-targeting poly ADP-ribose polymerase (PARP) inhibitor Olaparib suppressed tumor growth in the G4 subtype-representative GIST882 cell line. In vivo experiments demonstrated that Olaparib monotherapy significantly reduced tumor burden in GIST882 xenograft-bearing mice and synergized with imatinib.</p> Conclusion <p>We systematically deconstructed the molecular subtypes of primary GISTs by integrated genomic and transcriptomic analysis. A specific GIST subtype characterized by poor treatment responses and prognosis, marked by the activation of aerobic metabolism and HRD features, may be a potential candidate for PARP inhibitors.</p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Molecular classification identifies aggressive gastrointestinal stromal tumor subtype targetable by PARP inhibitors

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月1日

查看全文
  • Yuqi Ding,
  • Xiaoxue Ren,
  • Ye Yang,
  • Peiqi Cai,
  • Shuling Chen,
  • Yubin Xie,
  • Miaoling Tang,
  • Xiaofei Liu,
  • Shaoqing Huang,
  • Yu Yang,
  • Jiale Chen,
  • Wenxuan Xie,
  • Kaiyu Sun,
  • Xinhua Zhang

摘要

Purpose

Gastrointestinal stromal tumors (GISTs), the most common gastrointestinal sarcomas, experience a high rate of resistance to standard treatment tyrosine kinase inhibitor (TKI) imatinib, leading to tumor progression. Identifying non-responders and offering precise alternatives are crucial, however, multi-omics studies of GIST are limited, which hinders GIST biology understanding and novel drug development.

Methods

We performed whole-exome and transcriptomic sequencing on 106 primary GIST patients. Subtype-specific molecular features and therapeutic responses were further validated in vitro and in vivo.

Results

Unsupervised clustering analysis of RNA data classified them into four subtypes, including immune (G1), stromal (G2), proliferative (G3), and metabolic (G4) subtypes. The G4 subtype had more patients with primary non-gastric tumors, a poor response to neoadjuvant imatinib treatment and synchronous metastasis, with an overall poor prognosis. Notably, G4 subtype exhibited significantly enhanced aerobic metabolism. Moreover, G4 subtype harbored homologous recombination repair deficiency (HRD) signatures, with significantly reduced homologous recombination activity and upregulation of non-homologous repair pathways. By stratifying GIST cell lines into subtypes, we confirmed that the HRD-targeting poly ADP-ribose polymerase (PARP) inhibitor Olaparib suppressed tumor growth in the G4 subtype-representative GIST882 cell line. In vivo experiments demonstrated that Olaparib monotherapy significantly reduced tumor burden in GIST882 xenograft-bearing mice and synergized with imatinib.

Conclusion

We systematically deconstructed the molecular subtypes of primary GISTs by integrated genomic and transcriptomic analysis. A specific GIST subtype characterized by poor treatment responses and prognosis, marked by the activation of aerobic metabolism and HRD features, may be a potential candidate for PARP inhibitors.

Graphical Abstract